Cell therapy portfolio outperforms major indices year-to-date



On August 10 we created a model portfolio in Google Finance of 29 public companies in the cell therapy sector then we compared how that portfolio was doing against the major indices year-to-date (Since 1 January 2012).  See that post here.  Bottom line: even though we are still in a relatively bullish market, the CT portfolio was doing better.  Significantly better.
So how is the sector portfolio doing now that we've been through three quarters?
CT model portfolio compared to 3 major indices YTD
In case you can't read the image above, the blue line represents the cell therapy portfolio and here are the stats on performance since 1 January 2012:
  • Cell Therapy Portfolio:  +24.44%
  • Dow Jones:  +4.5%
  • S+P 500:  +6.78%
  • Nasdaq:  +10.26%
The only change I've made to the portfolio of 29 companies listed in our August 10 post is to add Thermogenesis (KOOL).  Today its stock is at .968 up from .7 at the beginning of the year.
You do or should know, I'm no financial analyst.  I'm not entirely sure what assumptions are behind this 'model portfolio' or precisely what one should take from this snapshot but what is clear to me is that at least from one perspective the sector is treating investors fairly well.
I certainly welcome comments from more sophisticated investors or analysts.  In fact, if anyone with that kind of experience or expertise wants to write a guest post on this blog providing a more sophisticated commentary on what this all means, I would very much welcome the contribution.
In the meantime, I hope this helps.
_________________
Post-publication addition:
Carter Gould, Associate Biotech Analyst at Dawson James Securities emailed me to point out that the cell therapy portfolio is simply riding the bull wave of biotech in general and and the portfolio has not done even half as well as the broader biotech (BTK) index which is up 45% YTD.  All very true.  Here is a YahooFinance snapshot of the BTK performance vs the three major indices.















Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/ediPNE1NBDw/cell-therapy-portfolio-outperforms.html

Hydration forces as a tool for the optimization of core-shell nanoparticle vectors for cancer gene therapy

Soft Matter, 2012, Advance ArticleDOI: 10.1039/C2SM26389K, PaperM. J. Santander-Ortega, M. de la Fuente, M. V. Lozano, M. E. Bekheet, F. Progatzky, A. Elouzi, I. F. Uchegbu, A. G. SchatzleinThe high cationic charge density of the polymers used in synthetic gene therapy vectors makes these systems toxic and induces non-specific interactions with blood components.To cite this article before page numbers are assigned, use the DOI form of citation above.The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Soft Matter latest articles)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Source:
http://www.medworm.com/index.php?rid=6595717&cid=c_449_59_f&fid=33814&url=http%3A%2F%2Ffeeds.rsc.org%2F~r%2Frss%2FSM%2F~3%2FK_FJvpDomew%2FC2SM26389K

Yamanaka and the Frailty of Peer Review


More than one back story exists on
Shinya Yamanaka and his Nobel Prize, but one that has received little
attention this week also raises questions about hoary practice of
peer review and publication of research – not to mention the
awarding of billions of dollars in taxpayer dollars.

The Yamanaka tale goes back to a 2010
article in the New Scientist magazine by Peter Aldous in which the
publication examined more than 200 stem cell papers published from
“2006 onwards.” The study showed an apparent favoritism towards
U.S. scientists. Also specifically reported were long delays in
publication of Yamanaka's papers, including in one case 295 days.
Here is part of what Aldous wrote,

“All's fair in love and war, they
say, but science is supposed to obey more noble ideals. New findings
are submitted for publication, the studies are farmed out to experts
for objective 'peer review' and the best research appears promptly
in the most prestigious journals. 

“Some stem cell biologists are crying
foul, however. Last year(2009), 14 researchers in this notoriously
competitive field wrote
to leading journals
 complaining of "unreasonable or
obstructive reviews". The result, they claimed, is that
'publication of truly original findings may be delayed or rejected.' 

“Triggered by this protest, New
Scientist scrutinised the dynamics of publication in the most
exciting and competitive area of stem
cell research
, in which cells are 'reprogrammed' to
acquire the versatility of those of an early-stage embryo. In this
fast-moving field, where a Nobel prize is arguably at stake,
biologists are racing feverishly to publish their findings in top
journals. 

“Our analysis of more than 200
research papers from 2006 onwards reveals that US-based scientists
are enjoying a significant advantage, getting their papers published
faster and in more prominent journals (find
our data, methods and analyses here
). 

“More mysterious, given his standing
in the field, is why two of Yamanaka's papers were among the 10 with
the longest lags. In the most delayed of all, Yamanaka reported that
the tumour-suppressing gene p53 inhibits the formation of
iPS cells. The paper took 295 days to be accepted. It was eventually
published by Nature in August 2009 alongside four similar
studies. 'Yamanaka's paper was submitted months before any of the
others,' complains Austin
Smith
 at the University of Cambridge, UK, who coordinated
the letter sent to leading journals. 

“Yamanaka suggests that editors may
be less excited by papers from non-US scientists, but may change
their minds when they receive similar work from leading labs in the
US. In this case, Hochedlinger submitted a paper similar to
Yamanaka's, but nearly six months after him. Ritu
Dhand
, Nature's chief biology editor, says that each paper
is assessed on its own merits. Hochedlinger says he was unaware of
Yamanaka's research on p53 before publication.”

Last week, Paul Knoepfler of UC Davis
wrote of other issues dealing with peer review, but coincidentally
also dealing with iPS cells. What New Scientist and Knoepfler are
discussing is not an isolated situation. It is part of a continuum of
complaints, both serious and self-interested but exceedingly
pervasive. A Google search today on the term “problems with peer
review” turned up 10.1 million references.  Writing on Ars Technica last year, Jonathan Gitlin, science policy analyst at the National
Human Genome Research Institute
,  summarized many of the issues, citing a “published” (our quotation marks)
study that said peer review doesn't work “any better than chance.”
Gitlin said,

“A common criticism is that peer
review is biased towards well-established research groups and the
scientific status quo. Reviewers are unwilling to reject papers from
big names in their fields out of fear, and they can be hostile to
ideas that challenge their own, even if the supporting data is good.
Unscrupulous reviewers can reject papers and then quickly publish
similar work themselves.” 

At the $3 billion California stem cell
agency, peer review is undergoing some modest, indirect examination
nowadays. The agency is moving towards tighter scrutiny of budgets
proposed by applicants. And, following a record wave of appeals this
summer by disgruntled applicants rejected during peer review, it is
also moving to bring the appeal process under more control.
As the agency tries to move faster and
more successfully towards development of commercial therapies, it may
do well to consider also the frailties of its peer review process and the
perils of scientific orthodoxy.   

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/lESi4gQF2IA/yamanaka-and-frailty-of-peer-review.html

Yamanaka: 'Rejected, Slow and Clumsy'


This week's announcement of the Nobel
Prize
for Shinya Yamanaka brought along some interesting
tidbits, including who was “snubbed” as well as recollections
from the recipient.

Jon Bardin of the Los Angeles Times
wrote the “snubbed” piece and quoted Christopher Scott of
Stanford and Paul Knoepfler of UC Davis about the selection issues.
Bardin's piece mentioned Jamie Thomson and Ian Wilmut as scientists
who also could have been considered for the award but were not named.
Ultimately, Bardin wrote that the award committee was looking for a
“singular, paradigm shifting discovery,” which he concluded was
not the case with Thomson or Wilmut.
How Yamanaka arrived at his research
was another topic in the news coverage, much of it dry as dust.
However, Lisa Krieger of the San Jose Mercury News began her story
with Yamanaka's travails some 20 years ago. At the time, no one was returning his phone
calls as he looked for work, and he was rejected by
50 apparently not-so-farsighted American labs.
But that job search in 1993 came only after Yamanaka
decided he was less than successful as an orthopedic surgeon,
according to an account in JapanRealTime. “Slow and clumsy” was
how Yamanaka described himself.
And so he moved on to research. But
again he reported stumbling. In this case, he found a way to reduce
“bad cholesterol” but with a tiny complication – liver cancer.
That in turn sent him on a journey to learn how cells proliferate and
develop, which led him to the work that won the Nobel Prize.
Yamanaka said his original interest in
orthopedic medicine was stimulated by his father along with the treatments
for injuries young Yamanaka received while playing rugby and learning judo. The JapanRealTime account continued,

“'My father probably still thinks in
heaven that I’m a doctor,' he said in the interview(with Asahi
Shimbun
last April). 'IPS cells are still at a research phase and
have not treated a single patient. I hope to link it to actual
treatment soon so I will be not embarrassed when I meet my father
someday.'”

And then there was, of course, the much-repeated story from the researcher who shared the Nobel with Yamanaka, John Gurdon. He has preserved to this day a
report from a high school biology teacher that said the 15-year-old
Gurdon's desire to become a scientist was “quite ridiculous.”
The teacher, who is unnamed, wrote,

“If he can’t learn simple
biological facts he would have no chance of doing the work of a
specialist, and it would be a sheer waste of time, both on his part
and of those who would have to teach him.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/7J31SRIukpg/yamanaka-rejected-slow-and-clumsy.html

Yamanaka: ‘Rejected, Slow and Clumsy’


This week's announcement of the Nobel
Prize
for Shinya Yamanaka brought along some interesting
tidbits, including who was “snubbed” as well as recollections
from the recipient.

Jon Bardin of the Los Angeles Times
wrote the “snubbed” piece and quoted Christopher Scott of
Stanford and Paul Knoepfler of UC Davis about the selection issues.
Bardin's piece mentioned Jamie Thomson and Ian Wilmut as scientists
who also could have been considered for the award but were not named.
Ultimately, Bardin wrote that the award committee was looking for a
“singular, paradigm shifting discovery,” which he concluded was
not the case with Thomson or Wilmut.
How Yamanaka arrived at his research
was another topic in the news coverage, much of it dry as dust.
However, Lisa Krieger of the San Jose Mercury News began her story
with Yamanaka's travails some 20 years ago. At the time, no one was returning his phone
calls as he looked for work, and he was rejected by
50 apparently not-so-farsighted American labs.
But that job search in 1993 came only after Yamanaka
decided he was less than successful as an orthopedic surgeon,
according to an account in JapanRealTime. “Slow and clumsy” was
how Yamanaka described himself.
And so he moved on to research. But
again he reported stumbling. In this case, he found a way to reduce
“bad cholesterol” but with a tiny complication – liver cancer.
That in turn sent him on a journey to learn how cells proliferate and
develop, which led him to the work that won the Nobel Prize.
Yamanaka said his original interest in
orthopedic medicine was stimulated by his father along with the treatments
for injuries young Yamanaka received while playing rugby and learning judo. The JapanRealTime account continued,

“'My father probably still thinks in
heaven that I’m a doctor,' he said in the interview(with Asahi
Shimbun
last April). 'IPS cells are still at a research phase and
have not treated a single patient. I hope to link it to actual
treatment soon so I will be not embarrassed when I meet my father
someday.'”

And then there was, of course, the much-repeated story from the researcher who shared the Nobel with Yamanaka, John Gurdon. He has preserved to this day a
report from a high school biology teacher that said the 15-year-old
Gurdon's desire to become a scientist was “quite ridiculous.”
The teacher, who is unnamed, wrote,

“If he can’t learn simple
biological facts he would have no chance of doing the work of a
specialist, and it would be a sheer waste of time, both on his part
and of those who would have to teach him.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/7J31SRIukpg/yamanaka-rejected-slow-and-clumsy.html

Tighter Controls on Stem Cell Grant Budgets Hits Quorum Bump


SAN FRANCISCO – A move to tighten
budget controls on grants from the $3 billion California stem cell
agency stalled Monday, but it appears that the plan is headed for
ultimate approval.

The proposal was up for consideration
by the agency's directors' Science Subcommittee, which could not act
on it after it lost its quorum.
Members of the panel generally favored
the stronger budget controls, but had questions about the specifics
of implementing the plan during closed-door reviews of grant
applications. The proposal is likely to be altered to respond to
those concerns. It would then either come back to the Science
Subcommittee or go to the full board.
The plan would make it clear to
recipients of large grants that approval of an application by the
agency's governing board does not provide a carte blanche to
researchers. Ellen Feigal, senior vice president for research and
development, said it can be “extremely difficult” for CIRM staff
to deal with budget problems in grants following board approval.
The committee also approved a plan to
speed the application process on its next disease team round, which
is aimed at driving research into the clinic. The concept proposal
for that round is scheduled to come before directors later this
month. The round will be limited to “more mature stage” research
that is close to a clinical trial, if not in one. Feigal said 10 to
15 applications are expected.
Another proposal to add more millions
to CIRM's strategic partnership program was also approved.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/EqLIk55mLu4/tighter-controls-on-stem-cell-grant.html

Yamanaka and the Golden State


The iPierian biopharmaceutical company
in South San Francisco was quick to make a change in its web site
this morning after the Nobel Prize for medicine was announced.

Altered was the bio for one of its
scientific advisors, Shinya Yamanaka, to note that he had won the
Nobel. The bio is tucked away on the site, but it is likely that the
company, which specializes in iPS work, will figure out how to put
the news out front on its home page as well as issue a press release.
It was all part of the reaction today
in California to the Nobel for Yamanaka, who has substantial links to
the Golden State, including UCSF and the Gladstone Institutes.
Both enterprises moved with greater
deftness than iPierian. Yamanaka is a professor at UCSF and a senior
investigator at Gladstone, and the organizations quickly put together a news conference this morning that featured Yamanaka on a video
hook-up from Japan.
UCSF, which is allied with Gladstone,
issued a press release that quoted the president of Gladstone, R.
Sanders Williams
, who also mentioned the California stem cell agency.
Williams said,

“Dr. Yamanaka’s story is a
thrilling tale of creative genius, focused dedication and successful
cross-disciplinary science. These traits, nurtured during Dr.
Yamanaka’s postdoctoral training at Gladstone, have led to a
breakthrough that has helped propel the San Francisco Bay Area to the
forefront of stem cell research. Dozens of labs — often supported
by organizations such as the California Institute for Regenerative
Medicine (CIRM)
and the Roddenberry Foundation–have adopted his
technology.” 

CIRM, which is the state's $3 billion
stem cell effort, published an item on its blog quoting CIRM
President Alan Trounson. He said,

"There are few moments in science
that are undisputed as genuine elegant creativity and simplicity.
Shinya Yamanaka is responsible for one of those. The induced
pluripotent stem cells he created will allow us to interrogate and
understand the full extent and variation of human disease, will
enable us to develop new medicines and will forever change the way
science and medicine will be conducted for the benefit of mankind. An
extraordinary accomplishment by a genuinely modest and brilliant
scientist. He absolutely deserves a Nobel award.”

The CIRM item by Amy Adams, the
agency's communications manager, said that just five years after
Yamanaka's research,

“CIRM alone is funding almost $190
million in awards developing better ways of creating iPS cells and
using those cells to develop new therapies (the
full list of iPS grants is on our website
).”

One of the recipients of CIRM's iPS
cash is the well-connected iPierian, which has taken in $7.1 million.
Yamanaka, however, has never received a grant from the agency, and
it is not known whether he ever applied since CIRM releases only the
names of researchers whose applications were approved.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/RbQ09EsO8Qc/yamanaka-and-golden-state.html

Stem Cell Orthodoxy and Peer Review


Going against the grain can be
difficult as UC Davis stem cell scientist Paul Knoepfler learned
again in connection with his research that dealt with similarities
between cancer and iPS cells.

His “unsettling” findings troubled
some scientists who reviewed his paper prior to its publication in
September in Stem Cells and Development. (See here and here.)
As many readers know, iPS or
reprogrammed adult cells are currently a hot research avenue in stem
cell research because they avoid many of the ticklish ethical and
political problems connected with human embryonic stem cells.
Knoepfler shared his thoughts on the
publication and peer review process on his blog last week. He wrote,

“Not surprisingly...there are certain
members of the stem cell field who would rather focus away from the
ideas that iPS cells are similar in some respects to cancer.”

Knoepfler, whose research was financed
in part by the California stem cell agency, wrote,

“Once we had a manuscript together
comparing iPS cells to cancer cells, we sent it to several high
profile journals without much luck. We thought that the fact that our
data indicated that iPS cells are similar to cancer cells might make
reviewers and editors excited. We thought that the paper was novel
and thought provoking in a number of ways. At the same time I
realized the theme of the paper would be controversial. 

“I would say two general things about
the review process at the two journals that turned down the paper.
First, the reviewers at these journals were enormously helpful with
their suggestions and helped us improve the paper substantially.
Second, they were clearly very uncomfortable with the notion that iPS
cells are related in some ways to cancer so unsettled in fact that I
believe it influenced their reviews.”

At one journal, a reviewer said the
findings were either “not sufficiently novel” or “trivial.”
“Little useful insights” said another. And a third said, “many
unsettling results....”
Knoepfler commented on this blog,

“Yeah, it may be unsettling that iPS
cells share traits with cancer cells, but if that is the reality,
isn’t it important that people know that and think about it, talk
about it, and address the issue with eyes open?”

Knoepfler's item and similar comments
from other researchers that can found elsewhere on the Internet
indirectly raise questions about the California stem cell agency's process
of peer review of applications for hundreds of millions of dollars in
funding, especially in the wake of this summer's unprecedented rash of appeals of decisions by grant reviewers.
The key question is whether the agency's closed-door process reinforces orthodoxy or, in fact, is all but controlled by what
amounts to scientific conventional wisdom. Obviously, no researcher
likes to see a paper rejected or a grant denied. But the record
number of appeals at CIRM and other private complaints could well indicate
that potentially profitable proposals are receiving a less than
welcome reception behind closed doors from agency reviewers.
The agency's board itself is
hard-pressed to make such determinations. It is hamstrung by
procedures that do not permit it to expand an application directly –
only a staff-written summary. Names of applicants and institutions
are censored, although the board is required by law to discuss in
public most aspects of a research proposal. Exceptions are permitted for proprietary information. Additionally, a handful of the 29 members of the governing board do participate in the reviews, which come before final action by the board. 
Currently the agency is pushing hard to
commercialize stem cell research and fulfill at least some of the
promises to voters that were made in 2004. To do that, the agency may
well have to step outside of the normal comfort zone of the good
burghers of stem cell science.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/LITB6cXS-ZM/stem-cell-orthodoxy-and-peer-review.html

Academic medical centers face shrinking profits – what to do?

Here are some suggestions from the official AMA newsletter for 5 recommendations to help academic medical centers evolve, with my comments:

1. Build a brand name by holding faculty accountable for cost and quality. Mayo Clinic has mastered that and they offer a "subscription service" allowing local hospitals to gain quick access to Mayo experts - and to advertise that in the local press.

2. Become part of a larger community network. This is part of the "spokes of a wheel" concept to generate referrals to the tertiary center from the peripheral clinics and hospitals.

3. Increase effectiveness by maximizing use of extenders such as telemedicine and simulation technology. Mayo Clinic has a TeleStroke unit. Cleveland Clinic offers an "all-electronic" second opinion for a base price of $600.

4. Become an information hub. MayoClinic.com, the online patient information portal of the Mayo organization, is a good example of that concept.

5. Align research efforts with clinical and business strategies.

Bart Demaerschalk, M.D., neurologist and medical director of Mayo Clinic Telestroke, shows us how the smartphone technology works:

References:

Academic medical centers may face shrinking profits. Amednews staff. Posted April 4, 2012.
Image source: openclipart.org, public domain.

Posted at Clinical Cases and Images. Stay updated and subscribe, follow us on Twitter and connect on Facebook.


Source:
http://feedproxy.google.com/~r/CasesBlog/~3/7kHJXwMyiAc/academic-medical-centers-face-shrinking.html

The management of ingrowing toenails – BMJ review

Ingrowing toenails are common, cause serious disability, and affect mainly young men. Most patients with ingrowing toenails are usually male, between the ages of 15 and 40 years.

There is a spectrum to the clinical presentation with pain progressing to infection, hypergranulation, and finally chronic infection.

Ingrowing toenails can occur in normal or abnormally shaped nails.

Cases in abnormally shaped nails are more difficult to manage conservatively and usually require surgery

Historically, a recurrence rate of 13-50% has been reported after surgical treatment, although more recent papers have reported recurrence rates of less than 5%.

Symptoms are less likely to recur after partial nail avulsion and segmental phenol ablation than after simple nail avulsion or wedge excisions alone.

Podiatrist Dr. Matthew Neuhaus explains what an ingrown toenail is (video):

Ingrown toenail surgery by Dr. Leo Krawetz (video). Warning: graphic content, do not try this at home:

References:

The management of ingrowing toenails. BMJ, 2012;344:e2089.

Posted at Clinical Cases and Images. Stay updated and subscribe, follow us on Twitter and connect on Facebook.


Source:
http://feedproxy.google.com/~r/CasesBlog/~3/LV1EoDLb1cc/the-management-of-ingrowing-toenails.html

The life of a science article: From submission to citation, see a manuscript pass through Nature’s editorial process (video)

Source: Nature YouTube channel

Comments from Twitter:

Dean Giustini @giustini: Good one~

Link via the medical blog ScienceRoll.

Posted at Clinical Cases and Images. Stay updated and subscribe, follow us on Twitter and connect on Facebook.


Source:
http://feedproxy.google.com/~r/CasesBlog/~3/wYRbKeBWOEA/the-life-of-science-article-from.html

Bloodhound rocket test – whoosh or bang?

Almost exactly 15 years since the Thrust supersonic car broke the sound barrier and the land speed record, last week the team behind Bloodhound SSC tested the rocket system that they hope will break that record.

The Bloodhound engine roars into life © Stefan Marjoram

Based at RAF St Mawgan in Newquay, UK, the test brought together hundreds of engineers, sponsors, media and schoolchildren. The RAF base was chosen because of its hardened air shelters (HAS), bomb-proof hangars originally designed to protect fighter planes during the cold war. This meant that those of us gathered to watch would be well-protected if the rocket exploded.

The rocket system consisted of a Cosworth Formula One engine, a pump from a 1960s Blue Steel cruise missile, 400 litres of ultra-pure hydrogen peroxide and 180kg of solid rubber rocket fuel (HTPB). You might think that a Formula One engine would be used to power the wheels, but then Bloodhound isn’t one of the ‘small, slow cars that goes round in circles’, as its driver Andy Green describes F1 cars. In Bloodhound, that powerful engine is needed just to push the peroxide into the rocket chamber at a high enough pressure.

That peroxide is fed through a silver-plated grating to break it down into oxygen and water, releasing energy and raising the temperature to 600°C. The combination of high pressure oxygen and heat ignites the rubber fuel, burning at 3000°C and unleashing up to 27,000 pounds of thrust.

There were a lot of unknowns before the test: would the pump withstand the high pressure, would the fuel burn evenly, would the chamber withstand the high temperature? In a year’s time, Andy Green will be sitting directly in front of that rocket system and the team need to be certain that the answer to those questions is a resounding ‘yes’.

We assembled 200 metres from the rocket in a neighbouring HAS to watch the test streamed live. The atmosphere was tense as we sat in complete silence while the engineers went through the final checks and the bombproof doors closed behind us. On the screen we could see the rocket chamber pointing slightly downwards, held in place by a large concrete rig. As the engine roared into life and started pumping the peroxide, we could see the flame leaving the back of the chamber as the fuel rod ignited. The engineers then unleashed the full power of the engine, pumping the peroxide at 820psi – the equivalent pressure of four family cars sitting on your palm. At this point, for a split-second, the screen turned white as the camera tried to adjust for the brightness. This was just long enough for it to appear as if the rocket had exploded. That was always a possibility and the engineers had even said beforehand that an explosion would be better than nothing happening. Happily, the camera quickly adjusted to reveal the incredibly smooth shape of the flame bursting out of the chamber. But we didn’t need the camera to know that the rocket was burning steadily, we could feel it in the ground. The quaking of the earth and deafening roar were clear signs that the engineers had got it right.

After 10 seconds, when the fuel was exhausted, the hangar erupted in applause. We had just witnessed the largest rocket test in the UK for 20 years and it was a great success. The rocket will be tested four more times over the next year, before the first record attempt in South Africa in late 2013. But the team don’t just want to break the 763mph record; they want to smash it. In 2014 they will return to South Africa and push the car to 1000mph. Keep an eye on http://www.bloodhoundssc.com to follow them every step of the way.

Ian Le Guillou

Digg This  Reddit This  Stumble Now!  Share on Facebook  Bookmark this on Delicious  Share on LinkedIn  Bookmark this on Technorati  Post on Twitter  Google Buzz (aka. Google Reader)  

Source:
http://prospect.rsc.org/blogs/cw/2012/10/10/bloodhound-rocket-test-whoosh-or-bang/

Watch the Nobel prize in chemistry live as it’s announced

Speculation over who will win this year’s chemistry Nobel prize has been feverish. Is it the turn of the biologists again (an old complaint that the lack of a biology Nobel prize means those feckless biologists have to filch our prize!) à la the 2009 prize for the structure of the ribosome? Or will it be awarded for more traditional chemistry like the 2010 prize for cross-couplings? Or it could even be another one like last year’s prize for quasicrystals that came completely out of left field and surprised a lot of people. We don’t know! But, if you want to see the predictions people have been making and even the odds for them then check our blog post. Otherwise sit back, relax and we’ll soon know who’s taken the most prestigious gong in the sciences and then the nice people on the Nobel prize committee will explain why it’s important and what it all means.

Patrick Walter

Digg This  Reddit This  Stumble Now!  Share on Facebook  Bookmark this on Delicious  Share on LinkedIn  Bookmark this on Technorati  Post on Twitter  Google Buzz (aka. Google Reader)  

Source:
http://prospect.rsc.org/blogs/cw/2012/10/10/watch-the-nobel-prize-in-chemistry-live-as-its-announced/

Who will win the chemistry Nobel?

With the Ig Nobels behind us, CW Towers now waits with bated breath for the chemistry Nobel. The prize for medicine and physiology has already been handed to John Gurdon and Shinya Yamanaka for their work on understanding what makes a stem cell different to a mature, adult cell and how an adult cell can be transformed into a stem cell. This work could help produce a limitless supply of stem cells for therapeutic purposes without some of the ethical concerns that have dogged this promising medical technology. Supplies of stem cells are currently mostly derived from human embryos.

Today was the turn of physics. And that prize was taken by David Wineland and Serge Haroche for their work controlling quantum systems. Their research is seen as a first step on the road to creating quantum computers that would use ions or atoms as quantum bits. These quantum computers would calculate not just in ones and zeros, as conventional computers do, but have an extra state, a superposition that is both a one and a zero at the same time. This extra state, which relies on the weirdness of the way the quantum world works, holds the promise of making quantum computers vastly more powerful than any even the fastest binary supercomputer in existence.

Out of the sciences this leaves just the chemistry prize to go tomorrow morning – you can watch it live on our blog. And there are plenty of predictions out there of who’s in with a chance of taking home this prestigious gong.

Paul Bracher over at ChemBark has also put together his predictions and added a few more as he’s still smarting over not having Dan Shechtman’s quasicrystals down on his list for last year’s chemistry Nobel! He makes his predictions on a whole host of criteria, including the all-important gut feeling. Clearly he thinks it’s the biologists turn (as they don’t have their own Nobel prize) and has given nuclear hormone signalling the shortest odds.

Every year Thomson Reuters also puts together its predictions by doing some number crunching using Web of Knowledge to pick out those researchers whose work has been cited the most. One of the guys behind the Thomson Reuters picks has claimed that it has the best record of anyone at picking winners – although just not in the year they make those predictions! They’ve added gold catalysis, photocatalytic properties of titanium dioxide and quantum dots to their list for this year’s prize. Thomson’s says that after 11 years they’ve successfully predicted 26 Nobel laureates to date (although this also includes the other Nobel prizes) – we’ll have to wait and see how they do this year.

At the Curious Wavefunction, a whole host of predictions have been made, although he hasn’t put odds to them. Nuclear receptors again feature high up on the list. Other possibles include DNA fingerprinting, the synthesis of cholesterol-busting statin drugs and the discovery of chaperone proteins that help other proteins fold correctly.

There’s still time to have a flutter, so have a look through the list and make your own predictions! Who do you think will win the chemistry Nobel prize?

Patrick Walter

 

Digg This  Reddit This  Stumble Now!  Share on Facebook  Bookmark this on Delicious  Share on LinkedIn  Bookmark this on Technorati  Post on Twitter  Google Buzz (aka. Google Reader)  

Source:
http://prospect.rsc.org/blogs/cw/2012/10/09/who-will-win-the-chemistry-nobel/

Yum yum, liquid N2?

Probably best enjoyed without liquid nitrogen

Reports are coming out that an 18 year old woman has had her stomach removed after drinking a ‘nitro’ cocktail given a smoky effect using liquid nitrogen. It seems that outside of labs liquid nitrogen is proving quite the star turn… from making ice cream in Camden, to being used in cocktails around the country.

These cocktails seem to come in two types, either a small amount of liquid N2 is used to cool the drink without dilution and with added smoky effect, or much more N2 is used to whisk up a frozen cocktail, more N2 is then poured over for, again, that smoky effect. Basically, everyone wants a cocktail that looks like it comes from the set of an Addams family movie.

So what happened in this instance? Well, the bar isn’t commenting and its website and Facebook page are unavailable, but the wonders of cached websites suggest that the cocktails the bar serves were of the smoking but liquid variety. That at least removes the risk of super cooled ice causing burns, but I can just imagine after a few drinks you’re not going to wait for the ‘smoke’ to disappear. Peer pressure, ‘having fun’, whether it was some super cooled ice in the drink or the liquid nitrogen itself, it sounds like a recipe for disaster and in this instance it was.

I recall, as well as having fun freezing things with left over liquid nitrogen, getting some pretty serious warnings about how to use liquid nitrogen safely – don’t touch any of the pipes, use protective gloves, never take the lift with it and instead put the container in the lift and send it off, while you take the stairs. I even saw how items dipped quickly into liquid N2 did not freeze, because they were protected by an insulating layer of gaseous N(a phenomenon known as the Leidenfrost effect), but how if left in contact for longer tissue could be frozen and destroyed.  I somehow doubt the risks of liquid nitrogen were spelled out to the poor woman in the same way they were to me and so, at the age of 18, she has lost her stomach.

But, to counter some of the more alarmist news reporting going on today, liquid N2 is not toxic, it’s incredibly cold and used in a controlled manner it’s safe and can add drama to restaurant dining halls and labs alike. But I wouldn’t drive drunk, I wouldn’t go into the lab drunk and I’d not trust myself with liquid nitrogen when drunk.

Laura Howes

 

Digg This  Reddit This  Stumble Now!  Share on Facebook  Bookmark this on Delicious  Share on LinkedIn  Bookmark this on Technorati  Post on Twitter  Google Buzz (aka. Google Reader)  

Source:
http://prospect.rsc.org/blogs/cw/2012/10/08/liquid-nitrogen-not-toxic-stomach-removed/

Dexter Review: A Necessary Evil

What a terrific episode of Dexter.

Continuing the theme of Season 7 - Deb vs. Dexter vs. his Dark Passenger vs. her confusion on how to control it - "Buck the System" featured a number of tense, intriguing discussions between brother and sister, while posing the legitimately difficult question:

Is Dexter a necessary evil in the world?

Deb, Dex, Dead Body

For years, Dexter has rambled about change and fitting in and whether he can just be a normal human being. But he can't be. We've all known this for awhile and it's been refreshing this season to hear Dexter admit as much.

But does that mean there's no place for him in society? It was fascinating to watch Dexter actually let Deb into his universe, to take her along to the suspect stakeout and attempt to explain his routine and his rationale for who he selects. He really is trying; not to change, but to adapt to this new situation.

It made sense Deb would reject the notion at first out of sheer shock and disgust that her brother is a serial killer, not to mention that pesky detail that she's a police captain assigned to uphold the law. But then she got a first hand look at Ray, at the fact that monsters really do exist in the world and it's a simple fact that the system can't always bring them to justice.

Can she sign off on Dexter's murderous habit? Can she openly approve and even assist him with the kills? Of course not. It would be far too abrupt a change.

But can Deb try to turn a blind eye? Absolutely. What's the alternative? Arrest her brother? Lose the most important person in her life and walk around knowing that person actually could have saved a few innocent lives? These are sincerely interesting, ethical questions.

Dexter has never really tackled them before. Viewers were introduced to the character as a killer and to the show as a very dark comedy. We were just meant to accept his urges and go along for the ride. However, to borrow the most overly-used phrase in the television reviewing business, the game has now changed and the fascination with Season 7 so far hasn't been any kind of action or suspense.

It's been the moral quandary into which Dexter has placed Deb. It's impossible not to wonder what one would do in her situation and equally as difficult to come up with an answer.

Other developments outside of sibling showdowns this week:

  • Yvonne Strahovski debuted as Hannah McKay. It's not exactly hard to see why Chuck viewers were such big fans of the actress, but it's way too early to judge her role on Dexter. There's clearly a whole lot more to the character outside of her affection for plants.
  • Please tell me Quinn's plan was always to pump the stripper... for information. Up until her admission that she was being asked to do the same to him, Quinn came across like he really was just trying to tap some more inappropriate ass.
  • So long, Louis. The conclusion to this storyline felt a bit rushed and convenient. I was anxious to see how Dexter would deal with such a non-lethal nuisance in his life and the answer felt like a cop-out: he wouldn't. The foreign mob boss would do the job for him.
  • But now that mob knows the name Dexter Morgan, opening up the cat-and-mouse game this series often pulls off so well.

What did everyone else think? How would you react if were you in Deb's shoes? And are you as on board for this vastly improved seventh season as I am?


Source:
http://www.tvfanatic.com/2012/10/dexter-review-a-necessary-evil/

Mockingbird Lane Preview: Meet the New Munsters

Mockingbird Lane is coming to NBC.

This remake of The Munsters, which ran for three years on CBS in the mid-1960s, was originally filmed as a pilot for mid-season.

But NBC has scrapped those plans and will introduce viewers instead to Portia de Rossi's Lily, Eddie Izzard as Grandpa and the other members of this unusual family on October 26 as a one-night-only special.

Watch the first official trailer now:


Source:
http://www.tvfanatic.com/2012/10/mockingbird-lane-preview-meet-the-new-munsters/

Revenge Clips: What is Victoria’s Story?

ABC has released four clips from tomorrow night's Revenge, two of which involve the white-haired man (WHM) at various points. First, we see Victoria and Daniel meet in a familiar spot at Grayson Manor.

As mother and son ponder their own insomnia (and Emily Thorne's), Victoria claims that the press won't back off until she reveals her story. We then see a big piece of her story revealed via flashback:

That's a pretty big piece of the puzzle, with more sure to come. Now that he's dead, of course, Victoria will try to spin this slightly differently as she reenters Hamptons society and plots her next move.

Flash forward to the present and WHM has just been offed by Aiden, as seen in last week's "Resurrection." Emily's mysterious savior tells he she is compromising the mission by pursuing her mother.

Takeda and Aiden want to ensure she stays focused, but Ems has other ideas:

The two additional clips below show Victoria and family bracing for the media storm to come. She's planning on putting the rumors to rest once and for all, and calls on the family to put on a united front.

That doesn't include Emily, however. Daniel clearly misses her and has feelings for his next-door neighbor, but Victoria makes it clear she wants her gone. We wouldn't hold our breath if we were her ...

"Confidence" airs Sunday at 9 p.m. EST. Share your comments, views and predictions below!


Source:
http://www.tvfanatic.com/2012/10/revenge-clips-what-is-victorias-story/

Grey’s Anatomy Sneak Peeks: I’m Laughing, Just Not Externally

When Grey's Anatomy returns Thursday, a familiar face makes a triumphant and unexpected return.

Also, many miles away, another familiar face is asked to turn that frown upside down.

Cristina Yang is miserable in Minnesota, which her new boss (guest star Steven Culp) picks up on and seeks to change. Begrudgingly (and hilariously), she agrees, but that external smile belies deeper issues.

Back in Seattle, Alex gets a lecture from Callie about not sleeping with his intern, and none other than Dr. April Kepner shows up at the hospital, having been brought back by Hunt. The team is surprised to say the least, and she's clearly taken aback herself when she realizes Jackson changed his mind and did not go to Tulane.

Watch the awkwardness ensue in three clips from "Love the One You're With" below:


Source:
http://www.tvfanatic.com/2012/10/greys-anatomy-sneak-peeks-im-laughing-just-not-externally/